The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Provention has acquired all rights to teplizumab to be further developed as PRV-031 and licensing rights to MGD010 for development as PRV-3279.
read more
Alkahest announced the initiation of two Phase 2 clinical trials of ALK4290 in patients with the wet form of age-related macular degeneration.
read more
Merck announced a collaboration with Washington University in St. Louis, Missouri that could lead to the optimizing of nutritional supplements to ...
read more
Eli Lilly and Company announced an agreement to acquire AurKa Pharma, a company established by TVM Capital Life Science to develop oncology compound ...
read more
Janssen Research & Development
Janssen announced the European Commission has granted marketing authorization for JULUCA (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [...
read more
BERG announced the FDA has granted orphan-drug designation for BPM 31510, for the treatment of patients with Epidermolysis Bullosa.
read more
Aptinyx announced Allergan has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor ...
read more
Bayer announced the FDA has accepted the New Drug Application (NDA) submitted by its collaboration partner Loxo and granted Priority Review for ...
read more
Janssen Research & Development
Janssen announced the initiation of a Phase 1b/2 clinical development program studying JNJ-68284528, a CAR-T therapy directed against BCMA, in ...
read more
BlueWillow Biologics announced the issuance of a U.S. patent entitled "Cancer Vaccine Compositions And Methods Of Using The Same," to the University ...
read more
Daiichi Sankyo announced the first patient has been dosed in a global phase 2 study evaluating the efficacy and safety of DS-8201.
read more
Peloton Therapeutics announced dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology ...
read more
Translate Bio announced a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA ...
read more
Sage Therapeutics announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the FDA.
read more
Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“...
read more